Pomerantz LLP vyšetřuje společnost Certara kvůli možnému podvodu s cennými papíry a dalším nezákonným praktikám. Firma zároveň oznámila pokles tržeb ze služeb o 4 % na 57,2 mil. USD a bookings o 14 % na 66,6 mil. USD.
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Certara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services revenue declined 4% year-over-year to $57.2 million, while services bookings declined 14% year-over-year to $66.6 million. In discussing the quarter, Certara said that it saw “softer performance from Tier 1 customers in MIDD services” and that services performance was “mixed.” The Company also announced its exit from the regulatory business in their service segment. I n response to a question about consistency between software and services performance, Certara said that there had been “a lot of inconsistency and back and forth” over the last few quarters.
On this news, Certara’s stock price fell $1.18 per share, or approximately 19%, to close at $5.13 on May 11, 2026.
Then, on June 17, 2026, Certara announced that John Gallagher, the Company’s Chief Financial Officer, had notified Certara of his intent to resign from his office effective as of the end of the day on July 14, 2026.
On this news, Certara’s stock price fell $0.49 per share, or 8.13%, to close at $5.54 per share on June 18, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Pomerantz LLP vyšetřuje společnost Certara kvůli možnému porušení zákonů o cenných papírech. Firma už dříve oznámila pokles tržeb ze služeb o 4 % na 57,2 mil. USD, pokles služebních zakázek o 14 % na 66,6 mil. USD a odchod finančního ředitele Johna Gallaghera.
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Certara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services revenue declined 4% year-over-year to $57.2 million, while services bookings declined 14% year-over-year to $66.6 million. In discussing the quarter, Certara said that it saw “softer performance from Tier 1 customers in MIDD services” and that services performance was “mixed.” The Company also announced its exit from the regulatory business in their service segment. I n response to a question about consistency between software and services performance, Certara said that there had been “a lot of inconsistency and back and forth” over the last few quarters.
On this news, Certara’s stock price fell $1.18 per share, or approximately 19%, to close at $5.13 on May 11, 2026.
Then, on June 17, 2026, Certara announced that John Gallagher, the Company’s Chief Financial Officer, had notified Certara of his intent to resign from his office effective as of the end of the day on July 14, 2026.
On this news, Certara’s stock price fell $0.49 per share, or 8.13%, to close at $5.54 per share on June 18, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Pomerantz LLP vyšetřuje Certara kvůli možnému podvodu s cennými papíry a dalším nezákonným praktikám. Firma zároveň oznámila pokles výnosů ze služeb o 4 % na 57,2 milionu USD a bookings o 14 % na 66,6 milionu USD.
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Certara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services revenue declined 4% year-over-year to $57.2 million, while services bookings declined 14% year-over-year to $66.6 million. In discussing the quarter, Certara said that it saw “softer performance from Tier 1 customers in MIDD services” and that services performance was “mixed.” The Company also announced its exit from the regulatory business in their service segment. I n response to a question about consistency between software and services performance, Certara said that there had been “a lot of inconsistency and back and forth” over the last few quarters.
On this news, Certara’s stock price fell $1.18 per share, or approximately 19%, to close at $5.13 on May 11, 2026.
Then, on June 17, 2026, Certara announced that John Gallagher, the Company’s Chief Financial Officer, had notified Certara of his intent to resign from his office effective as of the end of the day on July 14, 2026.
On this news, Certara’s stock price fell $0.49 per share, or 8.13%, to close at $5.54 per share on June 18, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Certara spolupracuje s NVIDIA na rozšíření své AI platformy pro vývoj léků. BioNeMo Agent Toolkit má urychlit získávání poznatků v celém procesu vývoje.
New capabilities unify Certara's biosimulation software, products, datasets, and scientific expertise with AI-driven agents to deliver specialized insights for life sciences July 07, 2026 08:00 ET | Source: Certara
RADNOR, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, is partnering with NVIDIA to advance Certara's open integrated AI platform, unifying its scientific software, regulatory expertise, and proprietary datasets with AI-first, agentic frameworks.
The NVIDIA BioNeMo Agent Toolkit turns any AI agent into an autonomous life sciences scientist, providing access to NVIDIA’s full life science stack. Within Certara's platform, BioNeMo Agent Toolkit serves as one of several agentic frameworks available to clients, working alongside Certara's biosimulation models, regulatory expertise, and scientific teams to accelerate insight generation.
“Agentic AI combined with Certara's world-class scientists, validated models, and data keeps the scientist in the loop while delivering the speed, scale, and reproducibility our clients need to generate integrated evidence for regulators,” said Jon Resnick, Chief Executive Officer. “Our collaboration with NVIDIA intends to bring frontier AI to life sciences responsibly, at scale, and with the scientific rigor the industry demands.”
Specialized AI agents will reason over Certara's scientific models, data, and domain expertise to produce insights across the full development continuum — optimizing a dosing strategy with systems pharmacology models, interrogating a clinical dataset, simulating patient and trial scenarios, evaluating ADMET properties, assembling regulatory-ready evidence, and exploring early discovery hypotheses. Agentic AI augments biosimulation experts and scientific teams, delivering faster access to insights while keeping scientists at the center of decision-making.
“We believe it will become increasingly possible to computationally simulate human biology in ways that will transform the discovery and development of new medicines,” said Chris Bouton, Chief Technology Officer, Chief AI Officer. “Our collaboration with NVIDIA and addition of the BioNeMo Agent Toolkit to the integrated platform helps accelerate that vision.”
About Certara
Certara transforms drug discovery and development for good, helping scientists and clinical teams generate regulatory-grade evidence faster. Its solutions combine biosimulation, clinical intelligence, and regulatory science, and are embedded in the workflows of drug developers worldwide. Certara clients include more than 2,600 biopharmaceutical companies, academic institutions, and global regulatory agencies. Learn more at certara.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding Certara’s integrated platform, the collaboration with NVIDIA, the integration of NVIDIA BioNeMo Agent Toolkit, and the anticipated benefits, capabilities, availability, and impact of these technologies. These statements are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Certara undertakes no obligation to update any forward-looking statement except as required by law.
Investor Relations Contact:
David Deuchler
Gilmartin Group [email protected]
Pomerantz LLP vyšetřuje nároky jménem investorů společnosti Certara. Firma po slabších výsledcích za 1. čtvrtletí a oznámení odchodu CFO Johna Gallaghera čelila prudkému poklesu akcií.
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Certara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services revenue declined 4% year-over-year to $57.2 million, while services bookings declined 14% year-over-year to $66.6 million. In discussing the quarter, Certara said that it saw “softer performance from Tier 1 customers in MIDD services” and that services performance was “mixed.” The Company also announced its exit from the regulatory business in their service segment. I n response to a question about consistency between software and services performance, Certara said that there had been “a lot of inconsistency and back and forth” over the last few quarters.
On this news, Certara’s stock price fell $1.18 per share, or approximately 19%, to close at $5.13 on May 11, 2026.
Then, on June 17, 2026, Certara announced that John Gallagher, the Company’s Chief Financial Officer, had notified Certara of his intent to resign from his office effective as of the end of the day on July 14, 2026.
On this news, Certara’s stock price fell $0.49 per share, or 8.13%, to close at $5.54 per share on June 18, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
